Company THES ACQU

POINT Biopharma Inc., formerly Therapeutics Acquisition Corp, is a late-stage clinical precision oncology company. The Company focuses on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's product candidates include PNT2002 and PNT2003 for the treatment of prostate cancer and neuroendocrine tumors. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. PNT2003 combines a somatostatin-specific radioligand DOTATATE with lutetium-177 (177Lu-DOTATATE).